Clascoterone 5% topical solution shows promise as a new treatment for male androgenetic alopecia, offering significant hair growth improvements with minimal side effects.

A recent study compares AI models DeepSeek-R1 and ChatGPT-4o in providing accurate, accessible information on urticaria, with DeepSeek showing superior performance.

Pirtobrutinib significantly improved progression-free survival in treatment-naïve CLL compared with bendamustine plus rituximab.

Value-based care adoption in employer insurance requires replacing fragmented point solutions with unified, at-risk performance contracts that align vendors, providers, and members around total cost and quality goals.

Self-insured employers face regulatory challenges when adopting value-based contracts, requiring careful data governance, standardized metrics, and legal frameworks to align with federal value-based care models.

Employers struggle to define value from health care spending amid complexity and misaligned incentives. Achieving measurable outcomes requires transparency, incentive realignment, and gradual, employee-centered change.

A large review identifies 70 safety signals for bimekizumab, confirming known risks while revealing previously unreported adverse events.

Semaglutide, sotatercept, and bentracimab trials were attendees’ main focus at the American College of Cardiology 2025 Annual Scientific Session.

Artificial intelligence and lung cancer highlighted the top conference coverage from the Association of Cancer Care Centers Annual Meeting in Washington, DC.

Inebilizumab gains FDA approval for treating generalized myasthenia gravis, showing significant improvements in muscle strength and steroid reduction.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Five key oncology FDA approvals came through last month, expanding treatment options across multiple cancer types.

The oral medication could be used in gonorrhea that is resistant to antibiotics according to a new phase 3 clinical trial.

The novel biomarker APP performed comparably to Fibrosis-4 overall and showed improved cirrhosis detection in patients with diabetes.

Investigators will test whether adding anodal transcranial direct current stimulation to exergame-based rehabilitation improves short- and long-term cognitive outcomes in 80 adults with multiple sclerosis.

Genetic risk models and variant tools help to guide intensive interventions for high-risk carriers and personalized management for others.

Experts at a roundtable in Boston, Massachusetts, on November 3, 2025, discussed improving early Alzheimer disease diagnosis, addressing workforce and equity gaps, and expanding access to new disease-modifying therapies.

Adding ianalumab to eltrombopag significantly prolongs time to treatment failure, boosts 6-month response rates, and improves fatigue for adults with primary ITP.

Camizestrant significantly improves progression-free survival in advanced breast cancer patients with ESR1 mutations.

A low-energy total diet replacement program before colorectal cancer surgery helped patients lose weight safely, improved certain symptoms, and showed cost-effectiveness.

Financial and social barriers hinder access to specialized care and impact treatment outcomes for adolescents and young adults with leukemia.

New findings from 2 abstracts presented at SABCS reveal T-DXd regimens enhance outcomes and tolerability for patients with high-risk HER2-positive early breast cancer.

Both health care plans brought forward by Republican and Democratic senators, respectively, did not garner enough support from across the aisle.

More than one-quarter of US adults have a risk factor for severe RSV infection, but their eligibility for the RSV vaccine depends on their age.

AMCP Nexus 2025 explored innovative health care policies, oncology advancements, and the impact of new regulations on patient access and treatment outcomes.